Purpose
HEPATOCELLULAR CARCINOMA
Edited by: Tai Hato, Saitama Medical University, JapanReviewed by: Qigu Yao, Zhejiang University, China; Jinzhang Chen, Southern Medical University, China; Kunwar Shailubhai, Tiziana Life Sciences Plc, United States†These authors have contributed equally to this work and share first authorshipThis multicenter, open-label, phase Ib/II study aimed to assess the efficacy and safety of cadonilimab, a humanized, tetravalent, bispecific antibody plus lenvatinib in first-line treatment of advanced hepatocellular carcinoma (aHCC).